ALNYLAM PHARMACEUTICALS
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
ALNYLAM PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2002-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.alnylam.com
Total Employee:
1001+
Status:
Active
Contact:
617.551.8200
Total Funding:
3.88 B USD
Technology used in webpage:
Domain Not Resolving ReCAPTCHA Cloudflare JS CDN JS Apple Mobile Web App Capable ASP.NET IIS IIS 10 Apple Mobile Web App Status Bar Style HSTS IncludeSubdomains PreLoad
Similar Organizations
Agios Pharmaceuticals
Agios Pharmaceuticals is a biopharmaceutical company discovers and develops therapeutics in the field of cancer metabolism.
CASI Pharmaceuticals
CASI focus on building a pipeline through mutually beneficial business development transactions.
Collegium Pharmaceutical
Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a drugmaker company.
Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies.
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
PTC Therapeutics
PTC Therapeutics is a biopharmaceutical company that engages in the discovery, development and commercialization of small-molecule drugs.
Regeneron
Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Rhythm Pharmaceuticals
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Bausch Health
Bausch Health is a develops and markets medications used in the fields of neurology, dermatology and infectious diseases.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
2002-12-01
Board_member
2002-06-01
Current Employees Featured
John Maraganore CEO @ Alnylam Pharmaceuticals
CEO
2002-12-01
Lubomir (Lubo) Nechev Vice President Process and Analytical Sciences @ Alnylam Pharmaceuticals
Vice President Process and Analytical Sciences
2017-01-01
Roumen Radinov Director, Process Chemistry @ Alnylam Pharmaceuticals
Director, Process Chemistry
2012-01-01
Eric Raichle Vice President, Human Resources @ Alnylam Pharmaceuticals
Vice President, Human Resources
James Bilotta SVP, Chief Information Officer (CIO) @ Alnylam Pharmaceuticals
SVP, Chief Information Officer (CIO)
2015-10-01
Mary Beth DeLena VP, Legal @ Alnylam Pharmaceuticals
VP, Legal
2013-01-01
Steve Bossone Senior Vice President, Chief Patent Counsel @ Alnylam Pharmaceuticals
Senior Vice President, Chief Patent Counsel
2019-01-01
Analesa Smith Global Digital Media Buying and Operations @ Alnylam Pharmaceuticals
Global Digital Media Buying and Operations
Steve Bossone Vice President, Intellectual Property @ Alnylam Pharmaceuticals
Vice President, Intellectual Property
2010-08-01
Karen Frascello Director & Global Medical Affairs @ Alnylam Pharmaceuticals
Director & Global Medical Affairs
2019-01-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2003-09-07 | Ribopharma AG | Ribopharma AG acquired by Alnylam Pharmaceuticals | N/A |
Investors List
Blackstone Life Sciences
Blackstone Life Sciences investment in Post-IPO Equity - Alnylam Pharmaceuticals
Blackstone Credit
Blackstone Credit investment in Post-IPO Debt - Alnylam Pharmaceuticals
Regeneron
Regeneron investment in Post-IPO Equity - Alnylam Pharmaceuticals
Genzyme
Genzyme investment in Post-IPO Equity - Alnylam Pharmaceuticals
Takeda
Takeda investment in Post-IPO Equity - Alnylam Pharmaceuticals
Atlas Venture
Atlas Venture investment in Private Equity Round - Alnylam Pharmaceuticals
ARCH Venture Partners
ARCH Venture Partners investment in Private Equity Round - Alnylam Pharmaceuticals
Abingworth
Abingworth investment in Private Equity Round - Alnylam Pharmaceuticals
Cardinal Partners
Cardinal Partners investment in Private Equity Round - Alnylam Pharmaceuticals
Polaris Partners
Polaris Partners investment in Private Equity Round - Alnylam Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-28 | Alnylam Announces Planned CEO Leadership Transition |
Official Site Inspections
http://www.alnylam.com Semrush global rank: 653.26 K Semrush visits lastest month: 48.21 K
- Host name: 23.185.0.253
- IP address: 23.185.0.253
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Alnylam Pharmaceuticals"
Alnylam® Pharmaceuticals
Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.See details»
About Alnylam® Pharmaceuticals
ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a …See details»
Alnylam Pharmaceuticals - Wikipedia
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Comp…See details»
About Alnylam® Pharmaceuticals—Harnessing the …
Harnessing a Revolution in Biology for Human Health® Alnylam is the leading RNAi therapeutics company. We are a U.S.-based biopharmaceutical company with operations around the world. Founded in 2002 on a bold vision to turn …See details»
Alnylam® Pharmaceuticals—The Leading RNAi …
Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent …See details»
Alnylam Pharmaceuticals - Crunchbase Company …
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.See details»
Org Chart Alnylam Pharmaceuticals - The Official Board
The org chart of Alnylam Pharmaceuticals contains its 37 main executives including Yvonne Greenstreet, Jeff Poulton and Christine Lindenboom.See details»
Alnylam Pharmaceuticals - LinkedIn
Alnylam Pharmaceuticals | 225,355 followers on LinkedIn. Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach. | SILENCE ...See details»
HomePage | Alnylam 20th Anniversary
Aug 10, 2018 Alnylam’s ingenuity and perseverance in solving the challenges presented by pioneering science established a revolutionary new approach to drug development that enables rapid advancement of new therapies for …See details»
Alnylam Pharmaceuticals Press Release | Mar 05, 2025 | Alnylam ...
Mar 5, 2025 Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary Mar 05, 2025 CAMBRIDGE, Mass. -- …See details»
Alnylam Pharmaceuticals, Inc. - amga.org
Alnylam Pharmaceuticals has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with …See details»
Alnylam Corporate Fact Sheet
Alnylam P5x25 Commencing in 2022, Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around …See details»
Alnylam Request Management System
Alnylam may provide monetary or non-monetary support to charitable organizations to advance science, healthcare, education, or to further other genuine charitable purposes. Charitable …See details»
Alnylam Named a Newsweek Most Responsible Company for 2025
Feb 3, 2025 What's so special about Alnylam is the way our employees help to drive the work forward. There's a sense of accountability at every level of the organization, and it's that …See details»
Alnylam - 2025 Company Profile, Funding & Competitors - Tracxn
Aug 17, 2021 Alnylam - Developer of RNA interference-based therapeutics for multiple disorders. Public Company. Raised a total funding of $17M over 7 rounds from 15 investors.See details»
Better Together: Alnylam and Organized Customer Health Systems …
Apr 26, 2024 Learn More Alnylam’s award-winning team of Health System Directors have more than 75 years of combined expertise in creating and managing relationships with organized …See details»
Alnylam Named One of America's Most Responsible Companies …
Dec 6, 2023 Alnylam has been named one of America's Most Responsible Companies by Newsweek for the 2nd year in a row.See details»
Grants And Giving | Alnylam
GRANTS AND GIVING The Alnylam Grants and Giving Office is committed to supporting innovative, high-quality initiatives that provide healthcare professionals and patients with …See details»
US FDA expands approval for Alnylam's drug to treat rare heart …
Mar 20, 2025 Alnylam's Amvuttra first to treat both nerve and heart forms of ATTR-CM Pricing strategy crucial for Amvuttra's market share against oral options Alnylam is banking on the …See details»
2024 Year in Review & Look Ahead: CEO Yvonne Greenstreet …
3 days ago Alnylam CEO Yvonne Greenstreet reflects on the company's accomplishments in 2024 and highlights of the 2024 annual report.See details»